Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2017-09-15

Clinical Trial Update: Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors [Phase 3]

View source ↗

Summary

Phase 3 trial of tofacitinib in psoriatic arthritis patients with inadequate response to TNF inhibitors has completed; results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Tofacitinib (tofacitinib)

Snippet

Sponsor: Pfizer | Conditions: Psoriatic Arthritis | Phase 3 | Status: COMPLETED | Results posted: 2017-09-15